SPX3,845.08+13.69 0.36%
DIA310.41+0.70 0.23%
IXIC11,361.85+39.61 0.35%

BRIEF-Fulcrum Therapeutics Announces Proof-Of-Concept For Sickle Cell Disease Treatment

reuters.com · 06/10/2022 07:14
BRIEF-Fulcrum Therapeutics Announces Proof-Of-Concept For Sickle Cell Disease Treatment

- Fulcrum Therapeutics Inc FULC:

  • FULCRUM THERAPEUTICS ANNOUNCES PROOF-OF-CONCEPT FOR FTX-6058 IN SICKLE CELL DISEASE BASED ON INITIAL DATA FROM THE ONGOING PHASE 1B TRIAL

  • FULCRUM THERAPEUTICS INC - ACHIEVED UP TO 6.3% HEMOGLOBIN F (HBF) INDUCTION IN INITIAL SUBJECTS IN FIRST COHORT

  • FULCRUM THERAPEUTICS INC - HBF WAS INCREASING AT LAST MEASURED TIMEPOINT

  • FULCRUM THERAPEUTICS INC - FTX-6058 WAS GENERALLY WELL TOLERATED; NO SERIOUS TREATMENT EMERGENT ADVERSE EVENTS (TEAES) REPORTED

  • FULCRUM THERAPEUTICS INC - DATA SUPPORTS PROOF-OF-CONCEPT THAT FTX-6058 IS A NOVEL ORAL HBF INDUCER

Source text for Eikon: ID:nGNX7hGyDM

Further company coverage: FULC


((Reuters.Briefs@thomsonreuters.com;))